CONMED (CNMD) Aandelenoverzicht
CONMED Corporation, een medisch technologiebedrijf, ontwikkelt, produceert en verkoopt apparaten en apparatuur voor chirurgische ingrepen. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
CNMD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CONMED Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$44.25 |
| 52 Week Hoogtepunt | US$56.64 |
| 52 Week Laag | US$31.44 |
| Bèta | 0.93 |
| 1 maand verandering | 23.09% |
| 3 maanden verandering | 23.05% |
| 1 Jaar Verandering | -12.01% |
| 3 jaar verandering | -62.56% |
| 5 jaar verandering | -66.95% |
| Verandering sinds IPO | 2,112.50% |
Recent nieuws en updates
Narratiefupdate • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.
Narratiefupdate • Jul 02
CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside
Analysts have lowered their price expectations for CONMED, with the updated target moving to $40. This reflects a shift toward lower assumed revenue growth and P/E multiples, even as projected profit margins edge higher in their models.Recent updates
Narratiefupdate • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.Narratiefupdate • Jul 02
CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside
Analysts have lowered their price expectations for CONMED, with the updated target moving to $40. This reflects a shift toward lower assumed revenue growth and P/E multiples, even as projected profit margins edge higher in their models.
Narratiefupdate • Jun 18
CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset
Analysts have reset their price target on CONMED to $40, down from $52, citing a broader reassessment of medtech valuations in a year with fewer product cycles, along with rising concerns around healthcare utilization and inflation. Analyst Commentary Recent commentary on CONMED highlights that the lower US$40 price target sits within a broader reset for medtech valuations, rather than being tied to a single company specific issue.Narratiefupdate • Jun 04
CNMD: Reset Medtech Expectations Will Set Stage For 2026 Guidance Reassessment
Analysts have trimmed their price targets on CONMED, with figures such as BofA cutting its target to $40 and another firm moving to $39. This reflects a reset in medtech valuations, as well as concerns around product execution and limited near term catalysts.Narratiefupdate • May 20
CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset
Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.Narratiefupdate • May 01
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.Narratiefupdate • Apr 17
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Narratiefupdate • Apr 02
CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.Narratiefupdate • Mar 18
CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.Narratiefupdate • Mar 04
CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.Narratiefupdate • Feb 17
CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.Narratiefupdate • Feb 03
CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.Narratiefupdate • Jan 19
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.Narratiefupdate • Jan 05
CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).Narratiefupdate • Dec 20
CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Seeking Alpha • Dec 15
Conmed Taking On More Pain In The Pursuit Of Future Gain
Summary Conmed (CNMD) shares are nearing decade lows despite credible progress with supply issues and ongoing efforts to shift toward higher-growth, higher-margin products. Management accelerated the exit from the lower-margin gastroenterology business, trading near-term revenue and EPS dilution for an 80bp margin boost and improved strategic focus. AirSeal's attach rate remains pressured by Intuitive Surgical's dv5, but upside exists from non-robotic procedures and OUS and ACS market expansion. CNMD appears undervalued on DCF and EV/revenue, but lacks near-term growth catalysts and remains a high-risk value play pending tangible restructuring results. Read the full article on Seeking AlphaNarratiefupdate • Dec 06
CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.Narratiefupdate • Nov 22
CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.Narratiefupdate • Nov 07
CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.Analyse-artikel • Oct 06
These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Sep 12
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...Analyse-artikel • Aug 08
CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...Analyse-artikel • Jul 03
Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...Analyse-artikel • May 24
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...Analyse-artikel • May 17
CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...Analyse-artikel • Mar 31
Is CONMED (NYSE:CNMD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 28
Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking AlphaAnalyse-artikel • Feb 28
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...Analyse-artikel • Feb 08
CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...Analyse-artikel • Jan 20
CONMED Corporation (NYSE:CNMD) Looks Inexpensive But Perhaps Not Attractive Enough
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analyse-artikel • Jan 01
Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?
CONMED Corporation ( NYSE:CNMD ), might not be a large cap stock, but it saw a decent share price growth of 11% on the...Analyse-artikel • Dec 13
CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
The board of CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend on the 3rd of January, with...Rendement voor aandeelhouders
| CNMD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 5.7% | 5.3% | -1.5% |
| 1Y | -12.0% | -16.9% | 16.0% |
Rendement versus industrie: CNMD overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -16.9 % opleverde.
Rendement versus markt: CNMD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 16 % opleverde.
Prijsvolatiliteit
| CNMD volatility | |
|---|---|
| CNMD Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: CNMD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van CNMD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1970 | 3,900 | Pat Beyer | www.conmed.com |
CONMED Corporation, een medisch technologiebedrijf, ontwikkelt, produceert en verkoopt apparaten en apparatuur voor chirurgische ingrepen. Het bedrijf biedt orthopedische chirurgieproducten aan, waaronder BioBrace, TruShot met Y-Knot All-In-One Fixatiesysteem voor weke delen, Y-knot All-Suture Anchors en Agro Knotless Suture Anchors, die klinische oplossingen bieden aan orthopedische chirurgen voor de vergroting en het herstel van weke delen, evenals ondersteunende producten waaronder aangedreven resectie-instrumenten, vloeistofmanagement en visualisatiesystemen en de gerelateerde producten voor eenmalig gebruik die chirurgen in staat stellen minimaal invasieve sportmedische ingrepen uit te voeren. Het bedrijf levert ook batterij-aangedreven, autoclaveerbare, grote en kleine botsystemen voor gebruik in orthopedische, artroscopische, orale/maxillofaciale, podotherapeutische, spinale en cardiothoracale chirurgie onder de merknaam Hall surgical.
CONMED Corporation Samenvatting
| CNMD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.31b |
| Inkomsten(TTM) | US$54.85m |
| Inkomsten(TTM) | US$1.37b |
24.3x
Koers/Winstverhouding1.0x
P/S-verhoudingIs CNMD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CNMD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.37b |
| Kosten van inkomsten | US$627.64m |
| Brutowinst | US$742.87m |
| Overige uitgaven | US$688.02m |
| Inkomsten | US$54.85m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 29, 2026
| Winst per aandeel (EPS) | 1.82 |
| Brutomarge | 54.20% |
| Nettowinstmarge | 4.00% |
| Schuld/Eigen Vermogen Verhouding | 84.5% |
Hoe presteerde CNMD op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/28 04:42 |
| Aandelenkoers aan het einde van de dag | 2026/07/28 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CONMED Corporation wordt gevolgd door 16 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Travis Steed | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |